Lactobacillus Crispatus: What Human Research Shows, and Its Limits

Quick answer. Lactobacillus crispatus is a lactic acid bacterium that often dominates the vaginal microbiome, and observational studies link it with markers of vaginal health, including a lower risk of later bacterial vaginosis (BV) in one cohort. The best-known human trials tested specific strains placed in the vagina, such as L. crispatus CTV-05 (LACTIN-V) after antibiotic treatment for BV, not capsules taken by mouth. Evidence that a swallowed L. crispatus capsule reaches the vagina is limited and differs from strain to strain. In trials, side effects were usually mild and similar to placebo, but data on pregnancy and long-term use are limited.

What Lactobacillus crispatus is

L. crispatus is a species of bacteria. In 396 North American women without symptoms, vaginal communities fell into five groups: four were each dominated by one Lactobacillus species (L. crispatus, L. iners, L. gasseri or L. jensenii), and the fifth had fewer lactic acid bacteria and more strictly anaerobic bacteria. These groups are called community state types (CSTs); the L. crispatus-dominated group is CST I. Group frequency and average vaginal pH differed by ethnic group.

Its name has not changed. When taxonomists split the old Lactobacillus genus into 25 genera in 2020, L. crispatus stayed in Lactobacillus. Some species often sold with it moved; PubMed's subject headings now list Lacticaseibacillus rhamnosus and Limosilactobacillus reuteri, for example.

Strain matters. Under the FAO/WHO definition, probiotics are "live microorganisms which when administered in adequate amounts confer a health benefit on the host." The NIH Office of Dietary Supplements (ODS) notes that a probiotic is identified by genus, species and strain, and that effects can be strain-specific. Human studies have used coded strains such as CTV-05, IP 174178 and GAI 98322 (vaginal products) and LMG S-29995, M247, NTCVAG04 and CECT 30647 (oral products).

Forms. Trials used vaginal powder in a prefilled applicator (LACTIN-V), vaginal capsules and suppositories, and oral capsules, drinks and a yogurt drink.

What human studies have tested

Vaginal products are listed first. They are not oral supplements.

What the findings suggest

The vaginal microbiome (observational). In 199 women who have sex with women followed for a year, having L. crispatus at the start was linked to a lower risk of later BV (hazard ratio 0.18). In young South African women, diverse communities dominated by anaerobes other than Gardnerella carried more than 4 times the risk of acquiring HIV compared with L. crispatus-dominant ones. These associations do not show that adding L. crispatus causes better outcomes. Strength: consistent, but observational.

BV recurrence with vaginal L. crispatus. Two vaginal strains, CTV-05 and IP 174178, lowered recurrence after antibiotics in randomized trials. A 2026 analysis of the LACTIN-V trial found an L. crispatus-dominant microbiota at week 12 in 30% of users vs 9% on placebo. Strength: moderate, for those products. LACTIN-V's developer calls it a "microbiome-based biologic drug," and FDA guidance describes a live biotherapeutic product as a biological product intended to prevent, treat or cure a disease or condition, a drug use that is regulated differently from dietary supplements.

Recurrent urinary tract infection (UTI). The one placebo-controlled LACTIN-V trial in recurrent UTI found a lower rate that was not statistically significant, and a single-arm study of GAI 98322 suppositories in 28 women had no control group. A 2026 systematic review of 4 probiotic trials (616 women), not all of L. crispatus, found the most consistent trend with vaginal use. Strength: limited.

Oral products. Results are mixed. Reznichenko reported fewer BV recurrences, and a meta-analysis of three small trials of an oral four-strain mix including L. crispatus LbV 88 found lower Nugent scores (a lab score of vaginal bacteria); its authors also ran included trials. Qi found no better cure rates. Strength: limited and strain-specific.

Fertility. In a trial of 338 IVF patients with abnormal vaginal microbiota, clindamycin plus vaginal LACTIN-V did not raise pregnancy rates (42% vs 45% with double placebo).

Where the evidence is limited or conflicting

• Oral delivery depends on the strain. The one placebo-controlled oral study we found that tracked an L. crispatus strain with strain-specific tests did not detect it in the vagina, though it detected the L. gasseri strain given alongside at twice the dose.
• Colonization often fades. After dosing stopped at week 11, CTV-05 fell from 79% of users at week 12 to 48% at week 24. In a phase 1 trial of multi-strain vaginal products, strains appeared in 47 of 71 users, and 23 of those were still present at week 12. Among 87 participants aged 14–21 using vaginal CTV-05 capsules, colonization was less likely in those who already carried L. crispatus (51% vs 90%) or had vaginal sex in the first week.
• Who was studied. Most trials enrolled women being treated for BV; few enrolled healthy women.
• Symptoms and microbiome do not always match. In 88 women aged 40–62, Lactobacillus-dominant communities were not linked to fewer vulvovaginal symptoms. Vaginal communities also shift within days, especially around menstruation.
• Funding and design. Five of the six oral studies in the table list company-affiliated authors, and two had no control group. The LACTIN-V trials were NIH-funded, but the developer, Osel, supplied the product, and Osel staff co-wrote the BV trial, the South African trial and the pregnancy study. We found no published phase 3 trial of LACTIN-V.

What buyers say, and what the research shows

Our team analyzed about 4,000 public Amazon reviews (4,005) of 15 women's vaginal-health probiotic products, including our own, 9 of which list L. crispatus, collected in September and early October 2026. Counts show on how many products a theme was a leading one (at least 10% of weighted review mentions). Reviews show what buyers believe or report; they cannot show whether a product caused any change.

Belief: it should fix odor and balance pH. Odor was a leading reason for buying on 10 of the 15 products, and pH on 5. A fishy odor and a vaginal pH above 4.5 are two of the four clinical criteria used to diagnose BV. In women with diagnosed BV, two small trials of oral products containing L. crispatus reported less odor or discharge (one abstract does not give the comparison with placebo), while a third found no difference in discharge or odor compared with metronidazole alone. In healthy women, one placebo-controlled trial of an oral capsule containing L. gasseri, with or without L. crispatus, found no difference in vaginal pH from placebo after up to 18 days. We found no trial of oral L. crispatus that measured odor in women without a diagnosis. A new or lasting odor change is a reason to see a clinician.

Belief: the label has to say crispatus. On all 4 products built around L. crispatus, buyers often named L. crispatus, or a strain of it, when judging the product. Research points past the species to the strain: CECT 30647 was not found in the vagina after oral use, while NTCVAG04 was found in 8 of 12 women in an uncontrolled study, and a lab study found strain-to-strain differences in antimicrobial activity. A label reading "L. crispatus complex" without a strain code cannot be matched to any trial strain.

Belief: you should feel a difference within days. "Felt nothing" was a leading theme on 6 of the 15 products; slow results (weeks or months) on 5; fast results (days) on 2. Oral trials ran 18 to 120 days. Most measured lab results such as strain detection, Nugent score or BV recurrence. The few that tracked symptoms such as discharge or odor enrolled women with BV, and their results were mixed. Because vaginal communities shift on their own, a few days of feeling nothing, or something, says little.

Belief: more CFU means a better product. CFU counts were a leading way buyers judged 1 of the 15 products. We found no study comparing doses of oral L. crispatus; oral trials gave from 0.5 billion CFU of one L. crispatus strain a day (CECT 30647) to about 10 billion CFU a day of blends containing it. NIH ODS advises looking for the CFU count at the end of shelf life rather than at manufacture. A higher count does not show that a strain has been tested.

Safety

Vaginal products. In the LACTIN-V BV trial, treatment-related adverse events by week 24 occurred in 87% of LACTIN-V users and 79% on placebo, not a statistically significant difference; the most common were abnormal discharge, odor, irritation and itching, and no severe event was judged product-related. Other (unsolicited) adverse events were reported by 42% vs 29% (not statistically significant). Two LACTIN-V users stopped after a miscarriage, listed as adverse events. In smaller phase 1 and 2a trials, mostly mild events were spread evenly between LACTIN-V and placebo. In a phase 1 trial in women with recurrent UTI, 7 of 15 CTV-05 users had white blood cells in the urine without symptoms.

Pregnancy. An observational study of LACTIN-V in 61 pregnant women at high risk of preterm birth, with two authors from Osel, reported no serious adverse events. We found no completed controlled trial of oral L. crispatus in pregnancy; one (PrePOP) has a published protocol and has not reported results. Ask your obstetric clinician before use in pregnancy or breastfeeding, and follow your product label.

Oral products. In the Perez trial, 20 adverse events occurred across all groups, including placebo; none was severe.

General. NIH ODS states that probiotics are unlikely to cause harm in healthy people and that side effects are usually minor digestive symptoms such as gas. Reported infections mostly involved people who were severely ill or immunocompromised, and FDA has warned that probiotics given to preterm infants may cause serious infection. Our PubMed search found no case reports naming L. crispatus infection in the title. EFSA's "qualified presumption of safety" list includes L. crispatus, provided a strain carries no acquired resistance genes to clinically relevant antibiotics; this is a safety screen, not a health claim.

Medicines and limits. We found no documented drug interactions specific to L. crispatus. If you take antibiotics, antifungals or immune-suppressing medicines, ask a pharmacist or doctor first. The NIH ODS fact sheet sets no upper intake level for probiotics and does not list drug interactions.

What research does not establish

• That an oral L. crispatus supplement colonizes the vagina in most people who take it.
• That any L. crispatus supplement prevents or treats BV, urinary tract infections, yeast infections or any other condition.
• That results with one coded strain apply to a product that lists only the species.
• That results in women treated for BV apply to healthy women without symptoms.
• That use beyond about one year is safe or useful; most trials gave the product for 4 months or less.

How we reviewed the evidence

On October 24, 2026, we searched PubMed for clinical trials with "Lactobacillus crispatus" in the title or abstract (59 records), for "CTV-05" or "LACTIN-V" (43) and for oral L. crispatus studies with vaginal outcomes (43): 116 unique records, screened by title and abstract. Extra searches covered infection case reports, oral dose comparisons and drug interactions. We included human trials, cohort and cross-sectional studies, two systematic reviews (one with a meta-analysis) and one published trial protocol on vaginal and urinary outcomes, and excluded animal and lab-only studies (except one lab study on strain differences), heat-killed L. crispatus and other conditions. We read full texts where available and abstracts otherwise, and checked the NIH ODS fact sheet, FDA guidance on live biotherapeutic products and EFSA's QPS list. Review themes come from our team's internal Amazon review deep-dive (October 2026). Vinatura did not run any trials of L. crispatus.

Vinatura Research Perspective

We asked four questions of each study: was L. crispatus placed in the vagina or swallowed; which coded strain was tested; who took part; and was the outcome a lab result, a clinical recurrence or how people felt. Side by side, the studies split by route. The strongest designs, including the NIH-funded LACTIN-V trial, tested one strain placed in the vagina after antibiotics. The oral studies used other strains, often in blends; five of the six list company-affiliated authors, two had no control group, and the one placebo-controlled study that tracked its L. crispatus strain did not find it in the vagina. A species name on a label carries the reputation of these strain-specific trials without their data. Our assessment: the link between L. crispatus dominance and a healthy vaginal microbiome is consistent but observational; evidence for specific vaginal strains after BV treatment is moderate; evidence that oral L. crispatus colonizes the vagina or changes symptoms is limited and strain-specific. Independent placebo-controlled oral trials using strain-specific tests, results from PrePOP, and a phase 3 LACTIN-V trial would change this assessment.

Where this ingredient appears in Vinatura products

Women's Probiotic contains L. crispatus complex 50 mg (5 billion CFU, stated at time of manufacture) per serving, with L. rhamnosus, L. plantarum, L. reuteri, L. gasseri and L. acidophilus complexes, in a delayed-release capsule taken by mouth. The label does not name strains. The label advises against use during pregnancy or nursing. The studies above did not test this product.

Frequently asked questions

Can an L. crispatus capsule taken by mouth reach the vagina? It depends on the strain, and evidence is limited. One placebo-controlled study did not detect its L. crispatus strain in the vagina; one uncontrolled study detected a different strain in 8 of 12 women.

Is LACTIN-V a supplement? No. It is a vaginal live biotherapeutic product tested in clinical trials. Its results apply to that strain and route, not to oral supplements.

Is L. crispatus safe? In trials, side effects were usually mild and similar to placebo. Data on pregnancy and long-term use are limited. People who are seriously ill or immunocompromised should talk with a doctor first, and everyone should follow the product label.

References

• Ravel J, et al. Vaginal microbiome of reproductive-age women. Proc Natl Acad Sci U S A. 2011;108(Suppl 1):4680-4687. doi:10.1073/pnas.1002611107
• Gajer P, et al. Temporal dynamics of the human vaginal microbiota. Sci Transl Med. 2012;4(132):132ra52. doi:10.1126/scitranslmed.3003605
• Zheng J, et al. A taxonomic note on the genus Lactobacillus: description of 23 novel genera, emended description of the genus Lactobacillus Beijerinck 1901, and union of Lactobacillaceae and Leuconostocaceae. Int J Syst Evol Microbiol. 2020;70(4):2782-2858. doi:10.1099/ijsem.0.004107
• Hill C, et al. Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol. 2014;11(8):506-514. doi:10.1038/nrgastro.2014.66
• Cohen CR, et al. Randomized trial of Lactin-V to prevent recurrence of bacterial vaginosis. N Engl J Med. 2020;382(20):1906-1915. doi:10.1056/NEJMoa1915254
• Bloom SM, et al. Vaginal microbiota impacts of a Lactobacillus crispatus live biotherapeutic and predictors of colonization in randomized controlled trial. Cell Host Microbe. 2026;34(4):734-750.e10. doi:10.1016/j.chom.2026.03.003
• Hemmerling A, et al. Effect of the vaginal live biotherapeutic LACTIN-V (Lactobacillus crispatus CTV-05) on vaginal microbiota and genital tract inflammation among women at high risk of HIV acquisition in South Africa: a phase 2, randomised, placebo-controlled trial. Lancet Microbe. 2025;6(6):101037. doi:10.1016/j.lanmic.2024.101037
• Potloane D, et al. VIBRANT: a phase 1 randomized trial of multi-strain vaginal L. crispatus live biotherapeutic products in people with bacterial vaginosis. Cell Host Microbe. 2026;34(4):751-760.e5. doi:10.1016/j.chom.2026.02.016
• Bohbot JM, et al. Efficacy and safety of vaginally administered lyophilized Lactobacillus crispatus IP 174178 in the prevention of bacterial vaginosis recurrence. J Gynecol Obstet Hum Reprod. 2018;47(2):81-86. doi:10.1016/j.jogoh.2017.11.005
• Stapleton AE, et al. Randomized, placebo-controlled phase 2 trial of a Lactobacillus crispatus probiotic given intravaginally for prevention of recurrent urinary tract infection. Clin Infect Dis. 2011;52(10):1212-1217. doi:10.1093/cid/cir183
• Sadahira T, et al. Efficacy of Lactobacillus vaginal suppositories for the prevention of recurrent cystitis: a phase II clinical trial. Int J Urol. 2021;28(10):1026-1031. doi:10.1111/iju.14636
• Yauri-Idelfonso M, et al. Probiotic prophylaxis in adult women with recurrent uncomplicated urinary tract infections: a systematic review of randomized controlled trials. J Glob Antimicrob Resist. 2026;50:122-129. doi:10.1016/j.jgar.2026.06.006
• Haahr T, et al. Efficacy of clindamycin and LACTIN-V for in vitro fertilization patients with vaginal dysbiosis: a randomised double-blind, placebo-controlled multicentre trial. Nat Commun. 2025;16(1):5166. doi:10.1038/s41467-025-60205-6
• Reznichenko H, et al. Oral intake of lactobacilli can be helpful in symptomatic bacterial vaginosis: a randomized clinical study. J Low Genit Tract Dis. 2020;24(3):284-289. doi:10.1097/LGT.0000000000000518
• Perez M, et al. Lactobacillus gasseri CECT 30648 shows probiotic characteristics and colonizes the vagina of healthy women after oral administration. Microbiol Spectr. 2025;13(9):e0021125. doi:10.1128/spectrum.00211-25
• Qi F, et al. Orally administrated Lactobacillus gasseri TM13 and Lactobacillus crispatus LG55 can restore the vaginal health of patients recovering from bacterial vaginosis. Front Immunol. 2023;14:1125239. doi:10.3389/fimmu.2023.1125239
• Mändar R, et al. Impact of Lactobacillus crispatus-containing oral and vaginal probiotics on vaginal health: a randomised double-blind placebo controlled clinical trial. Benef Microbes. 2023;14(2):143-152. doi:10.3920/BM2022.0091
• De Leo V, et al. Vaginal colonization of women after oral administration of Lactobacillus crispatus strain NTCVAG04 from the human microbiota. Minerva Obstet Gynecol. 2023;75(5):432-439. doi:10.23736/S2724-606X.22.05087-4
• Di Pierro F, et al. Oral administration of Lactobacillus crispatus M247 to papillomavirus-infected women: results of a preliminary, uncontrolled, open trial. Minerva Obstet Gynecol. 2021;73(5):621-631. doi:10.23736/S2724-606X.21.04752-7
• Laue C, et al. Effect of a yoghurt drink containing Lactobacillus strains on bacterial vaginosis in women: a double-blind, randomised, controlled clinical pilot trial. Benef Microbes. 2018;9(1):35-50. doi:10.3920/BM2017.0018
• de Vrese M, et al. Impact of oral administration of four Lactobacillus strains on Nugent score: systematic review and meta-analysis. Benef Microbes. 2019;10(5):483-496. doi:10.3920/BM2018.0129
• Marrazzo JM, et al. Risks for acquisition of bacterial vaginosis among women who report sex with women: a cohort study. PLoS One. 2010;5(6):e11139. doi:10.1371/journal.pone.0011139
• Gosmann C, et al. Lactobacillus-deficient cervicovaginal bacterial communities are associated with increased HIV acquisition in young South African women. Immunity. 2017;46(1):29-37. doi:10.1016/j.immuni.2016.12.013
• Mitchell CM, et al. Vaginal microbiota and genitourinary menopausal symptoms: a cross-sectional analysis. Menopause. 2017;24(10):1160-1166. doi:10.1097/GME.0000000000000904
• Antonio MA, et al. Vaginal colonization by probiotic Lactobacillus crispatus CTV-05 is decreased by sexual activity and endogenous lactobacilli. J Infect Dis. 2009;199(10):1506-1513. doi:10.1086/598686
• Atassi F, et al. Diverse expression of antimicrobial activities against bacterial vaginosis and urinary tract infection pathogens by cervicovaginal microbiota strains of Lactobacillus gasseri and Lactobacillus crispatus. Front Microbiol. 2019;10:2900. doi:10.3389/fmicb.2019.02900
• Lagenaur LA, et al. Connecting the dots: translating the vaginal microbiome into a drug. J Infect Dis. 2021;223(12 Suppl 2):S296-S306. doi:10.1093/infdis/jiaa676
• Hemmerling A, et al. Phase 1 dose-ranging safety trial of Lactobacillus crispatus CTV-05 for the prevention of bacterial vaginosis. Sex Transm Dis. 2009;36(9):564-569. doi:10.1097/OLQ.0b013e3181a74924
• Hemmerling A, et al. Phase 2a study assessing colonization efficiency, safety, and acceptability of Lactobacillus crispatus CTV-05 in women with bacterial vaginosis. Sex Transm Dis. 2010;37(12):745-750. doi:10.1097/OLQ.0b013e3181e50026
• Czaja CA, et al. Phase I trial of a Lactobacillus crispatus vaginal suppository for prevention of recurrent urinary tract infection in women. Infect Dis Obstet Gynecol. 2007;2007:35387. doi:10.1155/2007/35387
• Bayar E, et al. Safety, tolerability, and acceptability of Lactobacillus crispatus CTV-05 (LACTIN-V) in pregnant women at high-risk of preterm birth. Benef Microbes. 2023;14(1):45-56. doi:10.3920/BM2022.0084
• Corbett GA, et al. Preterm-birth-prevention with Lactobacillus crispatus oral probiotics: protocol for a double blinded randomised placebo-controlled trial (the PrePOP study). Contemp Clin Trials. 2025;149:107776. doi:10.1016/j.cct.2024.107776
• National Institutes of Health, Office of Dietary Supplements. Probiotics: Fact Sheet for Health Professionals. Updated March 25, 2025. ods.od.nih.gov
• U.S. Food and Drug Administration. Early Clinical Trials With Live Biotherapeutic Products: Chemistry, Manufacturing, and Control Information; Guidance for Industry. June 2016. fda.gov
• European Food Safety Authority, BIOHAZ Panel. Updated list of QPS-recommended microorganisms for safety risk assessments carried out by EFSA. Version 26, September 17, 2026. doi:10.5281/zenodo.22812707

Editorial note: This article reviews published research for educational purposes. It does not establish the effects or safety of any specific supplement, including Vinatura products, and is not medical advice. Written by Vinatura Editorial Team. Last reviewed October 2026.